$HOOK
HOOKIPA Pharma Inc.

2022 Q2 Form 10-Q Financial Statement

#000155837022013174 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $2.746M $1.445M $3.895M
YoY Change -48.94% -72.74% -24.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.026M $4.972M $3.523M
YoY Change -1.35% 15.36% -24.56%
% of Gross Profit
Research & Development $16.15M $16.62M $22.42M
YoY Change -17.5% -17.58% 42.89%
% of Gross Profit
Depreciation & Amortization $860.0K $1.078M $1.228M
YoY Change -29.57% -2.27% -53.31%
% of Gross Profit
Operating Expenses $16.15M $16.62M $25.94M
YoY Change -17.5% -17.58% 27.42%
Operating Profit -$18.43M -$20.15M
YoY Change -4.47% 5.09%
Interest Expense $231.0K $243.0K -$221.0K
YoY Change 5.96% 10.96% 16.32%
% of Operating Profit
Other Income/Expense, Net $2.072M $2.179M $1.033M
YoY Change -3.0% 12.67% -64.5%
Pretax Income -$16.36M -$17.97M -$21.24M
YoY Change -4.65% 4.23% 70.29%
Income Tax $1.000K $0.00 $0.00
% Of Pretax Income
Net Earnings -$16.36M -$17.97M -$21.24M
YoY Change -4.65% 4.23% 70.29%
Net Earnings / Revenue -595.63% -1243.46% -545.19%
Basic Earnings Per Share -$0.23 -$0.40
Diluted Earnings Per Share -$0.23 -$0.40 -$645.7K
COMMON SHARES
Basic Shares Outstanding 72.20M 45.04M
Diluted Shares Outstanding 72.20M 45.04M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $117.9M $140.8M $65.92M
YoY Change 15.02% 10.28% -53.8%
Cash & Equivalents $117.9M $140.8M $65.92M
Short-Term Investments
Other Short-Term Assets $13.52M $13.93M $15.05M
YoY Change -32.5% 80.9% 85.78%
Inventory
Prepaid Expenses
Receivables $1.187M $703.0K $6.895M
Other Receivables $16.45M $15.62M $14.27M
Total Short-Term Assets $149.1M $171.1M $102.1M
YoY Change 3.92% 11.6% -40.45%
LONG-TERM ASSETS
Property, Plant & Equipment $16.95M $17.10M $16.35M
YoY Change 28.37% 30.53% 162.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.095M $1.796M $1.370M
YoY Change -60.3% -48.69% -28.27%
Total Long-Term Assets $23.14M $24.63M $23.91M
YoY Change 1.89% 48.39% 46.57%
TOTAL ASSETS
Total Short-Term Assets $149.1M $171.1M $102.1M
Total Long-Term Assets $23.14M $24.63M $23.91M
Total Assets $172.2M $195.7M $126.0M
YoY Change 3.64% 15.19% -32.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.637M $6.708M $8.762M
YoY Change -48.12% -17.19% 9.4%
Accrued Expenses $9.555M $9.607M $9.598M
YoY Change -39.74% 77.91% 35.18%
Deferred Revenue $9.828M $10.70M $5.538M
YoY Change 225.43% 47.68%
Short-Term Debt $0.00 $3.375M $0.00
YoY Change
Long-Term Debt Due $1.423M $0.00 $2.813M
YoY Change -49.4% -100.0% 1306.5%
Total Short-Term Liabilities $27.22M $31.23M $27.65M
YoY Change -19.64% 55.36% 30.8%
LONG-TERM LIABILITIES
Long-Term Debt $2.419M $1.766M $2.219M
YoY Change 3.95% -63.96% -53.77%
Other Long-Term Liabilities $2.246M $2.474M $2.648M
YoY Change 56.52% -49.51% 87.67%
Total Long-Term Liabilities $13.03M $16.55M $8.799M
YoY Change 105.39% 68.92% -16.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.22M $31.23M $27.65M
Total Long-Term Liabilities $13.03M $16.55M $8.799M
Total Liabilities $40.26M $47.78M $36.45M
YoY Change 0.09% 59.81% 15.02%
SHAREHOLDERS EQUITY
Retained Earnings -$257.1M -$240.7M -$222.8M
YoY Change 41.65% 51.44%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $132.0M $147.9M $89.59M
YoY Change
Total Liabilities & Shareholders Equity $172.2M $195.7M $126.0M
YoY Change 3.64% 15.19% -32.89%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$16.36M -$17.97M -$21.24M
YoY Change -4.65% 4.23% 70.29%
Depreciation, Depletion And Amortization $860.0K $1.078M $1.228M
YoY Change -29.57% -2.27% -53.31%
Cash From Operating Activities -$18.36M $1.733M -$13.24M
YoY Change -11.43% -112.04% 17.19%
INVESTING ACTIVITIES
Capital Expenditures -$1.632M $1.828M -$5.141M
YoY Change -64.71% 453.94% 928.2%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.632M -$1.828M -$5.141M
YoY Change -64.71% 453.94% 928.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $45.69M
YoY Change 36450.4%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.953M 75.29M -410.0K
YoY Change -3533.72% 74447.52% -100.55%
NET CHANGE
Cash From Operating Activities -18.36M 1.733M -13.24M
Cash From Investing Activities -1.632M -1.828M -5.141M
Cash From Financing Activities -2.953M 75.29M -410.0K
Net Change In Cash -22.94M 75.20M -18.79M
YoY Change -9.19% -614.14% -129.7%
FREE CASH FLOW
Cash From Operating Activities -$18.36M $1.733M -$13.24M
Capital Expenditures -$1.632M $1.828M -$5.141M
Free Cash Flow -$16.73M -$95.00K -$8.102M
YoY Change 3.86% -99.35% -24.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security12b Title
Security12bTitle
Common Stock
us-gaap Net Income Loss
NetIncomeLoss
-34324000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32785382
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
dei Trading Symbol
TradingSymbol
HOOK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
dei Entity Central Index Key
EntityCentralIndexKey
0001760542
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10118
dei Country Region
CountryRegion
+43
dei City Area Code
CityAreaCode
1
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58692528
dei Local Phone Number
LocalPhoneNumber
890 63 60
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.hookipapharma.com/20220630#CollaborationAndLicensingMember
CY2021Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.hookipapharma.com/20220630#CollaborationAndLicensingMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.hookipapharma.com/20220630#CollaborationAndLicensingMember
CY2022Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.hookipapharma.com/20220630#CollaborationAndLicensingMember
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72195007
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32804269
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38869
dei Entity Registrant Name
EntityRegistrantName
HOOKIPA PHARMA INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-5395687
dei Entity Address Address Line1
EntityAddressAddressLine1
350 Fifth Avenue, 72nd Floor, Suite 7240
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117918000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65921000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
523000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
566000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1187000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6895000
CY2022Q2 hook Receivables Tax Research Premium Current
ReceivablesTaxResearchPremiumCurrent
16453000
CY2021Q4 hook Receivables Tax Research Premium Current
ReceivablesTaxResearchPremiumCurrent
14271000
CY2022Q2 hook Prepaid Expenses And Other Current Assets
PrepaidExpensesAndOtherCurrentAssets
12996000
CY2021Q4 hook Prepaid Expenses And Other Current Assets
PrepaidExpensesAndOtherCurrentAssets
14482000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
149077000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
102135000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
418000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
425000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16952000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16352000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4670000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5673000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
90000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1095000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1370000
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
23135000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
23910000
CY2022Q2 us-gaap Assets
Assets
172212000
CY2021Q4 us-gaap Assets
Assets
126045000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5637000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8762000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9828000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5538000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1647000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1682000
CY2022Q2 hook Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8689000
CY2021Q4 hook Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8880000
CY2022Q2 us-gaap Loans Payable Current
LoansPayableCurrent
1423000
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
2792000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
27224000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27654000
CY2022Q2 us-gaap Loans Payable
LoansPayable
819000
CY2021Q4 us-gaap Loans Payable
LoansPayable
2219000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2988000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3911000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6981000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2246000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2648000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
13034000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8799000
CY2022Q2 us-gaap Liabilities
Liabilities
40258000
CY2021Q4 us-gaap Liabilities
Liabilities
36453000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
395307000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
317135000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6268000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4780000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257090000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222766000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
131954000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89592000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
172212000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126045000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2746000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5378000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4191000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10679000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16147000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19572000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32767000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39736000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5026000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5095000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9998000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9404000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
21173000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
24667000
us-gaap Costs And Expenses
CostsAndExpenses
42765000
us-gaap Costs And Expenses
CostsAndExpenses
49140000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18427000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19289000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38574000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38461000
CY2022Q2 hook Grant Income
GrantIncome
1958000
CY2021Q2 hook Grant Income
GrantIncome
2505000
hook Grant Income
GrantIncome
3845000
hook Grant Income
GrantIncome
4709000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
182000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
us-gaap Investment Income Interest
InvestmentIncomeInterest
189000
us-gaap Investment Income Interest
InvestmentIncomeInterest
14000
CY2022Q2 us-gaap Interest Expense
InterestExpense
231000
CY2021Q2 us-gaap Interest Expense
InterestExpense
218000
us-gaap Interest Expense
InterestExpense
474000
us-gaap Interest Expense
InterestExpense
437000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
163000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-158000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
691000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-216000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2072000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2136000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4251000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4070000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16355000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17153000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34323000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34391000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16356000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17153000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16356000
hook Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-523000
hook Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
12323000
us-gaap Net Income Loss
NetIncomeLoss
-34391000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1001000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
293000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1488000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-183000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17357000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16860000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35812000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34574000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
89592000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 hook Adjustments To Additional Paid In Capital At Market Issuance Cost
AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost
142000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-487000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1621000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-17968000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
147929000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1001000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
131954000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
156123000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
125000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-476000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1521000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-17238000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
140055000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
112000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
293000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2627000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17153000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
125934000
us-gaap Profit Loss
ProfitLoss
-34324000
us-gaap Profit Loss
ProfitLoss
-34391000
us-gaap Share Based Compensation
ShareBasedCompensation
3002000
us-gaap Share Based Compensation
ShareBasedCompensation
4148000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1938000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2321000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-156000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-33000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5267000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-444000
hook Increase Decrease In Receivable Research Incentives
IncreaseDecreaseInReceivableResearchIncentives
3399000
hook Increase Decrease In Receivable Research Incentives
IncreaseDecreaseInReceivableResearchIncentives
1357000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
186000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-177000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
923000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
52254000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39897000
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
5011000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1833000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
457000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12193000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1364000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-864000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1006000
hook Increase Decrease In Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
299000
hook Increase Decrease In Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
11008000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
239000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2176000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16626000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35129000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3460000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4954000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3460000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4954000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
22000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
51000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
29625000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
45689000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
237000
us-gaap Repayments Of Debt
RepaymentsOfDebt
2952000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72340000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66912000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143177000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-307000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-327000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118859000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102953000
us-gaap Interest Paid Net
InterestPaidNet
22000
us-gaap Interest Paid Net
InterestPaidNet
24000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
hook Property And Equipment Additions In Accounts Payable And Accrued Expenses
PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses
145000
hook Property And Equipment Additions In Accounts Payable And Accrued Expenses
PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses
3426000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
234000
hook Lease Assets Derecognized Upon Lease Cancellation
LeaseAssetsDerecognizedUponLeaseCancellation
16000
CY2022Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0075
CY2021Q4 hook Accrued Social Security Contributions Current
AccruedSocialSecurityContributionsCurrent
250000
us-gaap Repayments Of Debt
RepaymentsOfDebt
3000000.0
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of the business and organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HOOKIPA Pharma Inc. (“HOOKIPA” or the “Company”) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the name of Hookipa Biotech, Inc. under the laws of the State of Delaware in February 2017 as a fully-owned subsidiary of Hookipa Biotech AG. In June 2018, the Company changed its name from Hookipa Biotech, Inc. to HOOKIPA Pharma Inc. and in order to effectuate the change of the jurisdiction of incorporation, the Company acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH. HOOKIPA is headquartered in New York, with European research and preclinical development operations headquartered in Vienna, Austria. In April 2019, the Company closed its initial public offering (“IPO”) and its common stock started trading on the Nasdaq Global Select Market under the ticker symbol “HOOK”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities and may not ultimately lead to a marketing approval and commercialization of a product. Even if the Company’s drug development efforts are successful, it is uncertain if and when the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p>
CY2022Q2 hook Accrued Unearned Grant Income Current
AccruedUnearnedGrantIncomeCurrent
411000
us-gaap Net Income Loss
NetIncomeLoss
-34300000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-75700000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards and the valuation of current and non-current loans payable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 11, 2020 the World Health Organization designated COVID-19 as a global pandemic. The Company believes the extent of the COVID-19 pandemic’s impact on the Company’s business, results of operations and financial condition has been, and will continue to be driven by many factors, most of which are beyond the Company’s control and ability to forecast. Because of these uncertainties, the Company cannot estimate how long or to what extent the pandemic will impact its operations. The Company’s accounting estimates and assumptions may change over time in response to COVID-19 and the change could be material in future periods. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.</p>
us-gaap Repayments Of Debt
RepaymentsOfDebt
0
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
5.38
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6114168
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the three and six months ended June 30, 2022 and June 30, 2021 the net proceeds from the Company’s offerings have been deposited in bank accounts with investment grade U.S. financial institutions and have been partially invested in money market funds. The money market funds, held in U.S. dollars, are primarily invested in U.S. and foreign short-term debt obligations. As of June 30, 2022 and December 31, 2021, the Company’s cash and cash equivalents included smaller amounts of cash balances held in accounts with European banks at the Company’s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2022 and December 31, 2021, Gilead Sciences, Inc. (“Gilead”) accounted for the majority of the accounts receivable balance. For the six months ended June 30, 2022 and June 30, 2021 Gilead accounted for the majority of the Company’s revenues. Other customers accounted for less than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.</p>
hook Number Of Combined Performance Obligation For Each Research Program
NumberOfCombinedPerformanceObligationForEachResearchProgram
1
hook Number Of Research Program Performance Obligations
NumberOfResearchProgramPerformanceObligations
2
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
hook Collaborative Arrangement Number Of Preclinical Research Programs
CollaborativeArrangementNumberOfPreclinicalResearchPrograms
2
CY2022Q2 hook Collaborative Arrangement Contract Asset Relating To Sublicense Payment
CollaborativeArrangementContractAssetRelatingToSublicensePayment
300000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1097000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2913971
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23656000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22718000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6704000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6366000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16952000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16352000
CY2022Q2 hook Receivables Tax Research Premium Current
ReceivablesTaxResearchPremiumCurrent
16500000
CY2021Q4 hook Receivables Tax Research Premium Current
ReceivablesTaxResearchPremiumCurrent
14300000
CY2022Q2 hook Grant Income Incentive Program
GrantIncomeIncentiveProgram
1700000
CY2021Q2 hook Grant Income Incentive Program
GrantIncomeIncentiveProgram
2300000
hook Grant Income Incentive Program
GrantIncomeIncentiveProgram
3400000
hook Grant Income Incentive Program
GrantIncomeIncentiveProgram
4300000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.22
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1063000
CY2022Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
2242000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3667000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4754000
CY2022Q2 hook Accrued Social Security Contributions Current
AccruedSocialSecurityContributionsCurrent
370000
CY2021Q4 hook Accrued Unearned Grant Income Current
AccruedUnearnedGrantIncomeCurrent
693000
CY2021Q4 hook Accrued Sub License Fees
AccruedSubLicenseFees
304000
CY2022Q2 hook Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
2954000
CY2021Q4 hook Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
2165000
CY2022Q2 hook Accrued External General And Administration Expenses
AccruedExternalGeneralAndAdministrationExpenses
910000
CY2021Q4 hook Accrued External General And Administration Expenses
AccruedExternalGeneralAndAdministrationExpenses
629000
CY2021Q4 hook Accrued Expenses For Property And Equipment Acquisitions
AccruedExpensesForPropertyAndEquipmentAcquisitions
7000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
21000
CY2022Q2 hook Other Accrued Expenses And Liabilities Current
OtherAccruedExpensesAndLiabilitiesCurrent
377000
CY2021Q4 hook Other Accrued Expenses And Liabilities Current
OtherAccruedExpensesAndLiabilitiesCurrent
57000
CY2022Q2 hook Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8689000
CY2021Q4 hook Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8880000
CY2022Q2 hook Long Term Loans Payable Gross
LongTermLoansPayableGross
2793000
CY2021Q4 hook Long Term Loans Payable Gross
LongTermLoansPayableGross
6074000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
551000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32804269
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58692528
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1093000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1684000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1109000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
2793000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 hook Register For Resale Of Common Stock Additional Issuances
RegisterForResaleOfCommonStockAdditionalIssuances
P4M
CY2022Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
70200000
CY2019Q2 hook Share Based Payment Arrangement Option Number Of Common Stock Entitled For Each Option
ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption
1
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32785382
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0296
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0107
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0287
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0107
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.848
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.855
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.849
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.855
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4231178
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.21
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1640000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2028291
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.65
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
22096
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
123205
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.78
hook Weighted Average Series Convertible Preferred Shares Outstanding Converted Into Common Stock
WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
2978000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3200197
CY2022Q2 us-gaap Contractual Obligation
ContractualObligation
8500000
hook Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm
P9Y1M6D
hook Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue
4000
hook Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Used For Calculating Intrinsic Values
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
1.63
CY2021 hook Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Used For Calculating Intrinsic Values
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
2.33
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
237000
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1381000
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2627000
us-gaap Share Based Compensation
ShareBasedCompensation
3002000
us-gaap Share Based Compensation
ShareBasedCompensation
4148000
CY2022Q2 hook Weighted Average Series One Convertible Preferred Shares Outstanding Converted Into Common Stock
WeightedAverageSeriesOneConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
15800000
hook Weighted Average Series One Convertible Preferred Shares Outstanding Converted Into Common Stock
WeightedAverageSeriesOneConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
10300552
hook Income Tax Benefits Net Operating Losses Incurred
IncomeTaxBenefitsNetOperatingLossesIncurred
0
CY2021Q2 hook Income Tax Benefits Net Operating Losses Incurred
IncomeTaxBenefitsNetOperatingLossesIncurred
0
hook Income Tax Benefits Net Operating Losses Incurred
IncomeTaxBenefitsNetOperatingLossesIncurred
0
CY2022Q2 hook Income Tax Benefits Net Operating Losses Incurred
IncomeTaxBenefitsNetOperatingLossesIncurred
0
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
400000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4700000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5700000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
100000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4600000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1600000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3000000.0
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5600000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1700000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3900000
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
100000
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.014
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72195007
CY2022Q2 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
4500000
CY2022Q2 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
4000000.0
CY2022Q2 hook Licensing Fees Intellectual Property Licenses
LicensingFeesIntellectualPropertyLicenses
400000
hook Licensing Fees Intellectual Property Licenses
LicensingFeesIntellectualPropertyLicenses
700000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-16356000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17153000
us-gaap Net Income Loss
NetIncomeLoss
-34324000
us-gaap Net Income Loss
NetIncomeLoss
-34391000
CY2022Q2 hook Weighted Average Number Of Shares Outstanding Basic And Diluted Before Conversion
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion
54698007
CY2021Q2 hook Weighted Average Number Of Shares Outstanding Basic And Diluted Before Conversion
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion
29826269
hook Weighted Average Number Of Shares Outstanding Basic And Diluted Before Conversion
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion
46694976
hook Weighted Average Number Of Shares Outstanding Basic And Diluted Before Conversion
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion
29807382
CY2022Q2 hook Weighted Average Series Convertible Preferred Shares Outstanding Converted Into Common Stock
WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
1697000
CY2021Q2 hook Weighted Average Series Convertible Preferred Shares Outstanding Converted Into Common Stock
WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
2978000
hook Weighted Average Series Convertible Preferred Shares Outstanding Converted Into Common Stock
WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock
1697000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2022Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1000
CY2022Q2 hook Convertible Preferred Stock Shares Issuable Upon Conversion
ConvertiblePreferredStockSharesIssuableUponConversion
1697000
CY2022Q2 hook Convertible Preferred Stock Seriesa One Shares Issuable Upon Conversion
ConvertiblePreferredStockSeriesaOneSharesIssuableUponConversion
15800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6114168
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4304048

Files In Submission

Name View Source Status
0001558370-22-013174-index-headers.html Edgar Link pending
0001558370-22-013174-index.html Edgar Link pending
0001558370-22-013174.txt Edgar Link pending
0001558370-22-013174-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hook-20220630.xsd Edgar Link pending
hook-20220630x10q.htm Edgar Link pending
hook-20220630xex31d1.htm Edgar Link pending
hook-20220630xex31d2.htm Edgar Link pending
hook-20220630xex32d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
hook-20220630_lab.xml Edgar Link unprocessable
hook-20220630_cal.xml Edgar Link unprocessable
hook-20220630_def.xml Edgar Link unprocessable
hook-20220630_pre.xml Edgar Link unprocessable
hook-20220630x10q_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable